Abstract
Contributions of glial cells to neuroenergetics have been the focus of extensive debate. Here we provide positron emission tomography evidence that activation of astrocytic glutamate transport via the excitatory amino acid transporter GLT-1 triggers widespread but graded glucose uptake in the rodent brain. Our results highlight the need for a reevaluation of the interpretation of [18F]FDG positron emission tomography data, whereby astrocytes would be recognized as contributing to the [18F]FDG signal.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sokoloff, L. Dev. Neurosci. 15, 194–206 (1993).
Mazziotta, J.C., Phelps, M.E., Miller, J. & Kuhl, D.E. Neurology 31, 503–516 (1981).
Mosconi, L. et al. J. Nucl. Med. 49, 390–398 (2008).
Nehlig, A. & Coles, J.A. Glia 55, 1238–1250 (2007).
Figley, C.R. & Stroman, P.W. Eur. J. Neurosci. 33, 577–588 (2011).
Volterra, A. & Meldolesi, J. Nat. Rev. Neurosci. 6, 626–640 (2005).
Pellerin, L. & Magistretti, P.J. J. Cereb. Blood Flow Metab. 23, 1282–1286 (2003).
Pellerin, L. & Magistretti, P.J. J. Cereb. Blood Flow Metab. 32, 1152–1166 (2012).
Pellerin, L. & Magistretti, P.J. Proc. Natl. Acad. Sci. USA 91, 10625–10629 (1994).
Voutsinos-Porche, B. et al. Cereb. Cortex 13, 1110–1121 (2003).
Voutsinos-Porche, B. et al. Neuron 37, 275–286 (2003).
Magistretti, P.J. & Pellerin, L. Mol. Psychiatry 1, 445–452 (1996).
Rothstein, J.D. et al. Nature 433, 73–77 (2005).
Zimmer, E.R. et al. J. Cereb. Blood Flow Metab. 35, 1169–1174 (2015).
Lehre, K.P., Levy, L.M., Ottersen, O.P., Storm-Mathisen, J. & Danbolt, N.C. J. Neurosci. 15, 1835–1853 (1995).
Chugani, H.T., Phelps, M.E. & Mazziotta, J.C. Ann. Neurol. 22, 487–497 (1987).
Phelps, M.E. & Mazziotta, J.C. Science 228, 799–809 (1985).
Choi, H. et al. Neuroimage 99, 226–236 (2014).
Lauritzen, M. J. Cereb. Blood Flow Metab. 21, 1367–1383 (2001).
Jack, C.R. Jr. et al. Lancet Neurol. 12, 207–216 (2013).
Zimmer, E.R., Parent, M.J., Cuello, A.C., Gauthier, S. & Rosa-Neto, P. Trends Neurosci 37, 629–641 (2014).
Furuta, A., Rothstein, J.D. & Martin, L.J. J. Neurosci. 17, 8363–8375 (1997).
Souza, D.G., Bellaver, B., Souza, D.O. & Quincozes-Santos, A. PLoS One 8, e60282 (2013).
Debernardi, R., Magistretti, P.J. & Pellerin, L. Brain Res. 850, 39–46 (1999).
Souza, D.G. et al. Neurochem. Res. 41, 1578–1586 (2016).
Worsley, K.J. et al. Hum. Brain Mapp. 4, 58–73 (1996).
Acknowledgements
We thank D. Onofre Souza, L. Valmor Cruz Portela, F. Urruth Fontella and A. Silva da Rocha from the Department of Biochemistry at UFRGS for fruitful discussions and for helping to conduct biochemical assays. This work was supported by a grant from iMSE from GIST and by the National Research Foundation of Korea (NRF:2013R1A2A2A01067890 to H.-I.K.), the Canadian Institutes of Health Research (CIHR; MOP-11-51-31 to P.R.-N. and MOP-142417 to E.H.), the Alan Tiffin Foundation, the Alzheimer's Association (NIRG-08-92090 to P.R.-N.), the Fonds de la recherche en santé du Québec (Chercheur boursier), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), the Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), the INCT for Excitotoxicity and Neuroprotection and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Work in the laboratory of L.P. is financially supported by the department of Physiology, University of Lausanne.
Author information
Authors and Affiliations
Contributions
All authors participated on the conceptualization, design and interpretation of the experiments. E.R.Z., M.J.P., A.L., H.-I.K. and P.R.-N. were responsible for conducting imaging acquisitions and analysis. E.R.Z., D.G.S. and L.P. were responsible for conducting in vitro studies in cell cultures. C.L. and E.H. were responsible for conducting laser Doppler acquisitions and analysis. All authors critically revised and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Ceftriaxone increases astroglial glutamate transport and glucose utilization without affecting GLT-1 expression in cultured adult cortical astrocytes.
(a) Glial fibrillary acidic protein (GFAP, green) and DAPI (blue), (b) Vimentin (red) and DAPI (blue), (c) GLT-1 (green) and DAPI (blue), and (d) NeuN (red) and DAPI (blue). (e) GLT-1 immunocontent (n = 6, two-tailed unpaired t-test, t(10) = 0.5469, p= 0.5964). (f) [3H]2DG uptake assay (n = 9-14; One-way ANOVA corrected by Bonferroni, F(3,39) = 16.88, p <0.0001). (g) [3H]D-Aspartate uptake assay (n = 9, two-tailed unpaired t-test, t(16) = 2.71, p = 0.0155). (h) Glutamate concentration in the extracellular medium in presence or absence of CEF after 70 minutes (n = 7, two-tailed unpaired t-test, t(12) = 2.968, p = 0.0117), (i) Glutamate concentration before (green circle) and after incubation (basal, blue square; and CEF, orange triangle). *p < 0.05 and ****p < 0.0001. Dashed line (mean) and yellow-shadowed area (s.d.) represent glutamate levels in the medium before incubation. Data are presented as mean values ± s.d. and individual scatter plots. Scale bar 10 μm.
Supplementary Figure 2 Astrocytic glutamate transport activation via GLT-1 does not alter spontaneous locomotion in the open field.
(a) Group representative occupancy plot. (b) Dynamic raster plots displaying individual patterns of habituation. (c) Total distance travelled (t(28) = 0.0756, p = 0.942), (d) mobile time (t(28) = 0.0351, p = 0.972), (e) mean speed (t(28) = 0.242, p = 0.8106), (f) time in central zone (t(28) = 1.016, p = 0.3182), and (g) distance travelled (t(28) = 0.3128, p = 0.7568) in the central zone. n = 15 rats per group. Two tailed unpaired t-test. Data are presented as mean values ± s.d. and individual scatter plots.
Supplementary Figure 3 Averaged brain maps and astrocytic glutamate transport activation patterns.
(a) Baseline SUV averaged maps. (b) CEF challenge SUV averaged maps. (c) Dynamic raster plots displaying individual patterns of [18F]FDG uptake after astrocytic glutamate transport activation via GLT-1. n = 10 per group.
Supplementary Figure 4 GLT-1 mRNA expression in the mouse brain.
(a) Regional GLT-1 mRNA expression. (b) Correlation between regional averaged percentage of change (CEF challenge – baseline) and regional GLT-1 mRNA expression. (c) GLT-1 in situ hybridization in sagittal view. (d) GLT-1 mRNA expression in the prefrontal cortex. (e) GLT-1 mRNA expression in the hippocampus. (f) GLT-1 mRNA expression in the striatum. (g) GLT-1 mRNA expression in the thalamus. (h) GLT-1 mRNA expression in the cerebellum. All images were acquired from the Allen Mouse Brain Connectivity Atlas (Image credit: Allen Institute for Brain Science; ©2012 Allen Institute for Brain Science. Allen Mouse Brain Atlas [Internet]. Available from: http://mouse.brain-map.org).
Supplementary Figure 5 Astrocytic glutamate transport activation via GLT-1 disrupts region-to-region metabolic synchronicity.
Cross-correlation matrices: inter-subject cross correlation maps displaying region-to-region associations in the baseline (a) and CEF challenge (b) conditions. Metabolic networks: 3D brain surfaces displaying large-scale metabolic cross-correlation maps in the baseline (c) and in the CEF challenge (d) conditions. n = 10 rats per group. Size of white circles (hubs) indicates number of connections. Data presented as correlation values with False Discovery Rate (FDR) correction at p<0.05.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 (PDF 1203 kb)
Rights and permissions
About this article
Cite this article
Zimmer, E., Parent, M., Souza, D. et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci 20, 393–395 (2017). https://doi.org/10.1038/nn.4492
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.4492
This article is cited by
-
In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol
BMC Medical Imaging (2024)
-
Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Molecular Psychiatry (2024)
-
Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
Journal of Neurology (2024)
-
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review
European Journal of Nuclear Medicine and Molecular Imaging (2024)
-
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Molecular Neurodegeneration (2023)